A federal drug discount program, initially designed to assist low-income patients, is reportedly being utilized by nonprofit hospital systems, leading to increased medication costs and potential impacts on access to care. This situation is unfolding as legislative bodies consider expanding the program.
Story Highlights
- The 340B drug pricing program, intended as a safety net, is being used by hospital systems to generate revenue.
- Hospitals acquire discounted drugs and subsequently bill at full price, retaining the difference.
- Kansas lawmakers are currently debating Senate Bill 284, which proposes expanding hospital access to the 340B program.
- Concerns exist that program utilization may contribute to higher drug prices, clinic closures, and reduced patient access.
Hospitals’ Use of 340B Program Examined
The federal 340B drug pricing program, established in 1992 to support safety-net providers serving vulnerable populations, has reportedly been adapted by large nonprofit hospital systems. These hospitals are acquiring medications at significant discounts and subsequently billing insurers and government programs at full price. This practice has raised questions regarding the program’s original intent and its potential effect on drug prices for consumers and taxpayers.
The program’s evolution accelerated following the Affordable Care Act in 2010, which expanded eligibility criteria. Hospitals began designating outpatient clinics as 340B-eligible, irrespective of the number of low-income patients served. Federal oversight bodies, including the Government Accountability Office (GAO) and the Office of Inspector General (OIG), have expressed concerns about the program’s oversight and accountability.
" The 340B program no longer fulfills its stated purpose. It fuels industry consolidation, drives up costs, and reduces access to care — especially in rural communities. "
The Blaze
— One Civilian (@OneCivilianUSA) October 18, 2025
Kansas Legislation and Potential National Implications
Kansas lawmakers are currently reviewing Senate Bill 284, a proposed bill that would broaden hospital access to the 340B program and modify drug manufacturer controls. Critics of the legislation suggest that its passage could intensify existing issues, potentially allowing more hospitals to benefit from the system without necessarily improving patient access or affordability. If enacted, SB 284 could establish a precedent for similar legislation in other states. As of October 2025, no significant federal reforms have been implemented despite ongoing discussions regarding healthcare costs.
While proponents of the 340B program assert its importance in funding uncompensated care, some evidence suggests that a majority of the benefits accrue to larger hospital systems. The expansion of the 340B program has also been linked to hospital consolidation, potentially impacting independent and rural clinics and affecting care options for vulnerable populations.
Impact on Patients and Rural Communities
The immediate effects attributed to the expansion of the 340B program include increased profits for large hospitals, reduced competition, and higher drug prices for consumers and insurers. In the long term, this consolidation may impact the sustainability of independent and rural clinics, limit patient choice, and deviate from the program’s original safety-net objective. Patients, particularly those in low-income and rural areas, may experience fewer care options and increased out-of-pocket expenses.
Economically, the program’s effects include higher overall healthcare spending and increased insurance premiums. Socially, disparities in healthcare access may be exacerbated. The political discourse surrounding 340B and similar programs is intensifying as the public seeks accountability from healthcare providers and lawmakers. The program’s current structure has been cited as an example of how government initiatives, without sufficient transparency and oversight, may not always benefit their intended recipients.
Calls for Program Reform
Watchdog organizations argue that the program’s design and lack of oversight have allowed it to become a revenue source for institutions rather than a support system for vulnerable patients. While some industry groups defend the program’s importance, independent audits and investigative reports have indicated a pattern of program utilization that may deviate from its original purpose. Without substantial reform, the trend of rising prices and reduced access may continue.
Watch the report: Hidden costs: The struggle to find hospital prices online
Sources:
- The hidden hospital scam driving up drug prices, coming to a state near you
- Prescription for Sanity: Ending the Great American Drug Price Scam
- Time to expose secret drug scam drug prices insurers American healthcare coupon Howard Dean
- Drug Copay Assistance Health Insurance
- 2025 National Health Care Fraud Takedown
